IDH1 and cholangiocarcinoma: Inhibitors of IDH1/2 act at the interface of epigenetic and metabolic vulnerabilities and have been FDA‐approved for the treatment of IDH‐mutant glioma, cholangiocarcinoma, and myeloid malignancies.